Metabolism-guided drug design
Abstract
Preclinical
* Corresponding authors
a Neuroscience Medicinal Chemistry, Pfizer Worldwide Research and Development, 700 Main Street, Cambridge, MA 02139, USA
b Cardiovascular, Metabolic and Endocrine Diseases Medicinal Chemistry, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, CT 06340, USA
c
Pharmacokinetics, Dynamics and Metabolism – New Chemical Entities, Pfizer Worldwide Research and Development, Cambridge, MA 02139, USA
E-mail:
amit.kalgutkar@pfizer.com
Tel: +1 617 551 3336
Preclinical
A. F. Stepan, V. Mascitti, K. Beaumont and A. S. Kalgutkar, Med. Chem. Commun., 2013, 4, 631 DOI: 10.1039/C2MD20317K
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content